Generating AI analysis...
AI Earnings Analysis
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Revenue | $4.55B | $4.18B | +8.88% |
Cost of Revenue | $1.31B | $1.2B | +9.71% |
Net Income | $1.22B | $1.22B | 0.00% |
EPS (Basic) | $2.68 | $2.64 | +1.52% |
EPS (Diluted) | $2.67 | $2.64 | +1.14% |
SG&A Expense | $1.13B | $1.06B | +6.31% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Total Assets | $14.16B | $13.75B | +3.03% |
Current Assets | $6.2B | $6.18B | +0.31% |
Total Liabilities | $9.21B | $9.13B | +0.84% |
Current Liabilities | $1.8B | $1.77B | +1.58% |
Stockholders' Equity | $4.97B | $4.63B | +7.37% |
Cash & Equivalents | $1.57B | $1.72B | -8.33% |
Long-Term Debt | $6.56B | $6.55B | +0.12% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Operating Cash Flow | $1.1B | $732M | +49.86% |
Investing Cash Flow | $-263M | $-296M | +11.15% |
Financing Cash Flow | $-1.29B | $-2.3B | +43.95% |
Share Buybacks | $872M | $607M | +43.66% |
D&A | $253M | $241M | +4.98% |
| Metric | Current | Previous | YoY Change |
|---|---|---|---|
Net Margin | 26.9% | — | — |
ROE | 24.6% | — | — |
ROA | 8.6% | — | — |
Current Ratio | $3.451 | — | — |
Debt to Equity | $1.854 | — | — |
Other companies in Pharmaceuticals